Reviewer’s report

Title: Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross sectional study

Version: 1 Date: 10 September 2013

Reviewer: Martin Klein

Reviewer’s report:

This is an interesting study into the effect of VEGFR TKI on cognitive functioning. While this study certainly has its value in this field of research, a number of issues should be addressed.

1. In the abstract under the header 'Background' no background information is provided, only what the authors will be studying. Why would anyone study this association becomes not clear from the abstract, while the introduction does provide solid evidence.

2. The authors state that VEGFR TKI has a negative impact on cognitive functioning, but how does this finding translate into daily clinical practice? Are there any choices at all in treatment and how are the potential side effect of treatment balanced against survival?

3. The authors report no consistent correlations between the results of hematology and chemistry blood tests and objective or subjective cognitive functioning. Since this was not the primary endpoint of this study do the authors think this is due to a lack of power?

4. What is the value of the reported subjective complaints against the reported cognitive performance?

5. The discussion is lengthy and is a bit off focus at times and thus should be shortened where possible.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a
statistician.

**Declaration of competing interests:**

'I declare that I have no competing interests'